BR9802542A - Células geneticamente modificsdas e seu uso na profilaxia ou terapia de distúrbios. - Google Patents

Células geneticamente modificsdas e seu uso na profilaxia ou terapia de distúrbios.

Info

Publication number
BR9802542A
BR9802542A BR9802542-2A BR9802542A BR9802542A BR 9802542 A BR9802542 A BR 9802542A BR 9802542 A BR9802542 A BR 9802542A BR 9802542 A BR9802542 A BR 9802542A
Authority
BR
Brazil
Prior art keywords
cells
disorders
therapy
gene
prophylaxis
Prior art date
Application number
BR9802542-2A
Other languages
English (en)
Inventor
Klaus Havemann
Rolf Dr Mueller
Hans-Harald Dr Sedlacek
Original Assignee
Hoechst Marion Roussel De Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19731154A external-priority patent/DE19731154C2/de
Application filed by Hoechst Marion Roussel De Gmbh filed Critical Hoechst Marion Roussel De Gmbh
Publication of BR9802542A publication Critical patent/BR9802542A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)

Abstract

Patente de Invenção: <B>"CéLULAS GENETICAMENTE MODIFICADAS E SEU USO NA PROFILAXIA OU TERAPIA DE DISTúRBIOS"<D>. A presente invenção refere-se a células para uso em terapia de gens, obteníveis por a) isolamento de células a partir do sangue ou de fluido contendo células do corpo; b) cultivo das células obtidas na etapa a) em um meio de cultivo de células compreendendo gangliosídeos, fosfolipídeos, glicolipídeos e/ou fatores de crescimento; c) alternativamente, imortalização das células obtidas na etapa a) ou b) por transformação com um oncogene, ativação de um oncogene ou inativação de um gen supressor; e d) alternativamente, transfecção das células obtidas na etapa a) e b) ou na etapa c) com um construto ácido nucléico para terapia de gens, compreendendo um gen efetor que pode ser ativado por alvo de maneira específica quanto a célula, de maneira específica quanto ao ciclo de célula, de maneira específica quanto ao vírus e/ou por hipoxia por sistemas promotores adequados, e ao uso dessas células para a produção de um agente terapêutico para o tratamento de um distúrbio selecionado a partir do grupo compreendendo tumores, leucemias, distúrbios auto-imune, alergias artrites, inflamações, rejeições de órgãos, reações transplante-versus-hospedeiro, distúrbios de coagulação do sangue, distúrbios de circulação, anemia, infecções, distúrbios de hormónios e dano do CNS.
BR9802542-2A 1997-07-21 1998-07-21 Células geneticamente modificsdas e seu uso na profilaxia ou terapia de distúrbios. BR9802542A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19731154A DE19731154C2 (de) 1997-07-21 1997-07-21 Genetisch veränderte Endothelzellen und deren Verwendung in der Prophylaxe oder Therapie von Erkrankungen
DE19752299 1997-11-26

Publications (1)

Publication Number Publication Date
BR9802542A true BR9802542A (pt) 2000-01-11

Family

ID=26038441

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9802542-2A BR9802542A (pt) 1997-07-21 1998-07-21 Células geneticamente modificsdas e seu uso na profilaxia ou terapia de distúrbios.

Country Status (14)

Country Link
US (1) US20020098166A1 (pt)
EP (1) EP0893493A3 (pt)
JP (1) JPH1189587A (pt)
KR (1) KR19990014018A (pt)
AR (1) AR015926A1 (pt)
AU (1) AU757960B2 (pt)
BR (1) BR9802542A (pt)
CA (1) CA2237698A1 (pt)
CZ (1) CZ227198A3 (pt)
HU (1) HUP9801634A3 (pt)
ID (1) ID20600A (pt)
PL (1) PL327624A1 (pt)
RU (1) RU2205029C2 (pt)
TR (1) TR199801395A2 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2787464B1 (fr) * 1998-12-21 2003-01-10 Neurotech Compositions pharmaceutiques comprenant des cellules endotheliales immortalisees pour la detection et/ou le traitement des sources angiogeniques et tout particulierement des cancers
US6815430B1 (en) 1999-04-02 2004-11-09 Hisamitsu Pharmaceutical Co., Inc. Gene expression base sequences for therapeutic use and drugs for gene therapy
AU5724499A (en) * 1999-09-23 2001-04-24 An-Go-Gen Inc. Cell-based gene therapy for the pulmonary system
US20030049635A1 (en) * 2000-11-08 2003-03-13 City Of Hope Measurement of mutation load using the p53 gene in human cells from paraffin embedded tissues
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
US7101977B2 (en) 2001-07-17 2006-09-05 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins
ES2353665T3 (es) 2002-03-15 2011-03-03 Duke University Ingeniería tisular.
US20030215426A1 (en) * 2002-04-02 2003-11-20 William Marsh Rice University Redifferentiated cells for repairing cartilage defects
EP1458853B1 (en) * 2002-05-16 2009-11-25 Absorber AB Methods of donor specific crossmatching
EP1644483A4 (en) * 2003-07-15 2006-11-29 Cedars Sinai Medical Center USE OF PLEIOTROPHINE FOR THE DIAGNOSIS, TREATMENT AND PREVENTION OF DISEASES
KR100676922B1 (ko) * 2005-06-29 2007-02-05 정하철 혈 표시용 반지
US8883507B2 (en) 2005-10-18 2014-11-11 The Regents Of The University Of Colorado Conditionally immortalized long-term hematopoietic stem cells and methods of making and using such cells
BRPI0817233A2 (pt) * 2007-09-28 2012-11-06 Intrexon Corp construções terapêuticas de gene de trca e bireatores para a expressão de moléculas bioterapêuticas, e usos das mesmas
WO2009139930A2 (en) 2008-05-16 2009-11-19 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
EP2746387A1 (en) * 2008-07-21 2014-06-25 Taiga Biotechnologies, Inc. Differentiated anucleated cells and method for preparing the same
DK2966084T3 (en) 2008-08-28 2018-08-06 Taiga Biotechnologies Inc MODULATORS OF MYC, PROCEDURES FOR USING SAME AND PROCEDURES FOR IDENTIFYING SUBSTANCES MODULATING MYC
CA2977820A1 (en) * 2008-11-25 2010-06-03 Otsuka Pharmaceutical Co., Ltd. Stem cell for therapeutic use which is derived from human monocyte, and method for inducing same
IN2012DE01792A (pt) 2012-06-11 2015-10-16 Council Scient Ind Res
CA3133302A1 (en) 2012-07-20 2014-01-23 Taiga Biotechnologies, Inc. Enhanced reconstitution and autoreconstitution of the hematopoietic compartment comprising a myc polypeptide
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
US9365825B2 (en) 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
JP7011827B2 (ja) 2015-09-24 2022-02-10 セレクト バイオセラピューティクス リミテッド 移植に用いる間葉系幹細胞（ｍｓｃ）を増殖させる方法
CA3045017A1 (en) 2016-12-02 2018-06-07 Taiga Biotechnologies, Inc. Nanoparticle formulations
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0578769A4 (en) * 1991-04-04 1995-08-16 Us Health Immortalization of human endothelial cells
FR2681609B1 (fr) * 1991-09-24 1994-12-30 Centre Nat Rech Scient Lignees de cellules endotheliales cerebrales immortalisees, leur procede de preparation et leurs applications en tant que modele d'etude de la physiopathologie cerebrale.

Also Published As

Publication number Publication date
AU757960B2 (en) 2003-03-13
KR19990014018A (ko) 1999-02-25
CZ227198A3 (cs) 1999-02-17
PL327624A1 (en) 1999-02-01
RU2205029C2 (ru) 2003-05-27
JPH1189587A (ja) 1999-04-06
HUP9801634A3 (en) 2003-07-28
HU9801634D0 (en) 1998-09-28
TR199801395A2 (xx) 1999-02-22
ID20600A (id) 1999-01-21
HUP9801634A2 (hu) 1999-06-28
EP0893493A3 (de) 2002-12-04
EP0893493A2 (de) 1999-01-27
AU7746698A (en) 1999-02-04
US20020098166A1 (en) 2002-07-25
AR015926A1 (es) 2001-05-30
CA2237698A1 (en) 1999-01-21

Similar Documents

Publication Publication Date Title
BR9802542A (pt) Células geneticamente modificsdas e seu uso na profilaxia ou terapia de distúrbios.
Gregoriadis et al. Enzyme-containing liposomes alleviate a model for storage disease
Srinivasan et al. The species variation of RNA methylase
Click et al. Enhancement of antibody synthesis in vitro by mercaptoethanol
Hoober et al. Epidermal growth factor: I. The stimulation of protein and ribonucleic acid synthesis in chick embryo epidermis
BR0010648A (pt) Utilização de microesferas biodegradáveis que liberam um agente anticanceroso radiossensibilizador, processo de preparação de microesferas biodegradáveis, e, suspensão constituìda de uma solução estéril
Harrington Effect of X irradiation on the priming activity of DNA
BR9712978A (pt) Vìrus de dna de não-mamìferos possuindo uma proteìna de revestimento alterada
ATE85080T1 (de) Menschlicher transformationswachstumsfaktor und vorlaeufer oder fragment hiervon, zellen, dna, vektoren und verfahren zu ihrer herstellung, zusammensetzungen und produkte, die diese enthalten, sowie davon abgeleitete antikoerper und diagnostizierverfahren.
Ryan et al. Chromatin template activity during aging in WI38 cells
Lance et al. The use of subcellular fractions to raise anti-lymphocytic serum
Askanas et al. Histochemistry of cultured aneural chick muscle. Morphological maturation without differentiation of fiber types
ES398962A1 (es) Un procedimiento para la preparacion de una composicion de enzima.
KR102257386B1 (ko) 줄기세포 재료 및 그 제조방법
Goldberg Lactate dehydrogenases in trout: Evidence for a third subunit
Tabachnick Studies on the Biochemistry of Epidermis: II. Some Characteristics of Deoxyribonucleases I and II of Albino Guinea Pig Pidermis and Saline Extracts of Hair
CN108220231A (zh) 一种干细胞培养基及其制备方法和应用
Finn et al. Transplacental passage of red cells in man
Roth A possible function of intracellular ribonucleases
BR9804769A (pt) Processo para tratar ou prevenir infecção por pestivìrus em um hospedeiro mamìfero tendo ou sendo suscetìvel a referida infecção,e , para tratar c~elulas de mamìferos em cultura, e, em mamìferos biológicos
Lozzio Lethal effects of fluorodeoxyuridine on cultured mammalian cells at various stages of the cell cycle
Rodighiero et al. A comparison between the photoreactivity of some furocoumarins with native DNA and their skin-photosensitizing activity
Richard et al. Biosynthesis of glycoproteins in the aortic wall study of intima microsomic mannosyl-transferase activity
Kay Effect of actinomycin on protein synthesis by lymphocytes
Jackson Chromosome aberrations in cultured human leukocytes treated with 8-ethoxycaffeine

Legal Events

Date Code Title Description
TC Change of name
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A,7A,8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1905 DE 10/07/2007.